iPSC Cell Therapy for Parkinson's Disease

Migration, Crosslink

📖

iPSC Cell Therapy for Parkinson's Disease

active

wiki page Created: 2026-04-02T07:18:59 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-ipsc-cell-therapy-park

📖 Wiki Page

therapeutic1582 wordssynced 2026-04-02

iPSC Cell Therapy for Parkinson's Disease

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">iPSC Cell Therapy for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Company</td>
<td>Product</td>
</tr>
<tr>
<td class="label">UC San Diego</td>
<td>CT1-DAP001</td>
</tr>
<tr>
<td class="label">BlueRock Therapeutics</td>
<td>BRT-DA01</td>
</tr>
<tr>
<td class="label">Aspen Neuroscience</td>
<td>ANPD001</td>
</tr>
<tr>
<td class="label">Kyoto University</td>
<td>iPSC-derived DA neurons</td>
</tr>
<tr>
<td class="label">Lundbeck/Oxford</td>
<td>SC2587</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Autologous (Aspen)</td>
</tr>
<tr>
<td class="label">Immune rejection</td>
<td>Minimal</td>
</tr>
<tr>
<td class="label">Manufacturing time</td>
<td>6-9 months</td>
</tr>
<tr>
<td class="label">Cost per dose</td>
<td>Very high</td>
</tr>
<tr>
<td class="label">Gene editing</td>
<td>Possible</td>
</tr>
<tr>
<td class="label">Scalability</td>
<td>Challenging</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>iPSC-derived</td>
</tr>
<tr>
<td class="label">Ethical concerns</td>
<td>Minimal</td>
</tr>
<tr>
<td class="label">Patient-specific</td>
<td>Yes</td>
</tr>
<tr>
<td class="label">Tumor risk</td>
<td>Lower</td>
</tr>
<tr>
<td class="label">Autologous possible</td>
<td>Yes</td>
</tr>
<tr>
<td class="label">Company</t

...

iPSC Cell Therapy for Parkinson's Disease

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">iPSC Cell Therapy for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Company</td>
<td>Product</td>
</tr>
<tr>
<td class="label">UC San Diego</td>
<td>CT1-DAP001</td>
</tr>
<tr>
<td class="label">BlueRock Therapeutics</td>
<td>BRT-DA01</td>
</tr>
<tr>
<td class="label">Aspen Neuroscience</td>
<td>ANPD001</td>
</tr>
<tr>
<td class="label">Kyoto University</td>
<td>iPSC-derived DA neurons</td>
</tr>
<tr>
<td class="label">Lundbeck/Oxford</td>
<td>SC2587</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Autologous (Aspen)</td>
</tr>
<tr>
<td class="label">Immune rejection</td>
<td>Minimal</td>
</tr>
<tr>
<td class="label">Manufacturing time</td>
<td>6-9 months</td>
</tr>
<tr>
<td class="label">Cost per dose</td>
<td>Very high</td>
</tr>
<tr>
<td class="label">Gene editing</td>
<td>Possible</td>
</tr>
<tr>
<td class="label">Scalability</td>
<td>Challenging</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>iPSC-derived</td>
</tr>
<tr>
<td class="label">Ethical concerns</td>
<td>Minimal</td>
</tr>
<tr>
<td class="label">Patient-specific</td>
<td>Yes</td>
</tr>
<tr>
<td class="label">Tumor risk</td>
<td>Lower</td>
</tr>
<tr>
<td class="label">Autologous possible</td>
<td>Yes</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Funding</td>
</tr>
<tr>
<td class="label">BlueRock Therapeutics</td>
<td>$1B+ (Bayer)</td>
</tr>
<tr>
<td class="label">Aspen Neuroscience</td>
<td>$220M+</td>
</tr>
<tr>
<td class="label">Cynata Therapeutics</td>
<td>Public (ASX:CYP)</td>
</tr>
</table>

Induced pluripotent stem cell (iPSC) therapy represents one of the most promising disease-modifying approaches for Parkinson's disease (PD). This therapeutic strategy aims to replace the dopaminergic [neurons](/entities/neurons) lost in [Parkinson's disease](/diseases/parkinsons-disease) by transplanting neurons derived from pluripotent stem cells into the [substantia nigra pars compacta](/cell-types/substantia-nigra-pars-compacta-parkinsons)—the brain region where these neurons degenerate.

Unlike symptomatic treatments that only manage motor symptoms (such as [levodopa](/therapeutics/levodopa), [dopamine agonists](/therapeutics/dopamine-agonists-parkinsons), or [MAO-B inhibitors](/therapeutics/selegiline)), iPSC cell therapy has the potential to halt or reverse disease progression by restoring the lost neuronal population and reconstituting dopaminergic signaling in the [nigrostriatal pathway](/cell-types/nigrostriatal-terminals-parkinsons)[@dopaminergic].

Mechanism of Action

Cell Replacement Strategy

iPSC-derived dopaminergic neuron therapy works through several key mechanisms:

Neuronal Replacement: Transplanted [iPSC-derived dopaminergic neurons](/cell-types/ipsc-derived-dopaminergic-neurons) replace dead or dysfunctional neurons in the [substantia nigra](/cell-types/substantia-nigra-dopamine-parkinsons)

Dopamine Production: These neurons synthesize and release [dopamine](/mechanisms/dopamine-biosynthesis-pathway), restoring neurotransmitter levels in the [striatum](/cell-types/nigrostriatal-terminals-parkinsons)

Circuit Integration: Neuronal axons grow and form synaptic connections with host neurons in the [basal ganglia circuit](/circuits/parkinson-basal-ganglia-circuit)

Trophic Support: Transplanted neurons secrete neurotrophic factors that support remaining endogenous neurons

Target Brain Regions

The primary target for transplantation is the putamen, a structure in the basal ganglia that receives dopaminergic input from the [substantia nigra](/cell-types/substantia-nigra-parkinsons). The putamen is the main region where dopamine deficiency manifests in PD patients.

Clinical Trial Landscape

Active Clinical Trials

UC San Diego — CT1-DAP001 (NCT06482268)

The CT1-DAP001 trial is a Phase 1 study of human iPS cell-derived dopaminergic progenitors for Parkinson's disease, sponsored by UC San Diego.

Trial Details:

Design: First-in-human, Phase 1 study
Sponsor: University of California San Diego
Cell Source: Human iPSC-derived dopaminergic progenitors
Trial ID: NCT06482268
Status: Recruiting

This trial represents an important addition to the iPSC cell therapy landscape for PD, contributing to the growing body of evidence for cell replacement therapy approaches.

BlueRock Therapeutics — BRT-DA01 (STEM-PD)

[BlueRock Therapeutics](/companies/bluerock-therapeutics), a Bayer AG company, is conducting the STEM-PD trial—the first Phase 1 clinical trial of pluripotent stem cell-derived dopaminergic neurons for Parkinson's disease[@stempd].

Trial Details:

Design: Open-label, dose-escalation study
Patients: Adults with advanced PD (Hoehn & Yahr stage 2.5-3)
Dosing: Single surgical implantation of ~70 million cells
Delivery: Stereotactic injection into bilateral putamen
Primary Endpoints: Safety and tolerability at 12 months
Secondary Endpoints: Motor function (MDS-UPDRS Part III), PET imaging of dopamine function

Cell Manufacturing:

Cell source: Human embryonic stem cells (hESCs)
Differentiation: Directed differentiation to midbrain dopaminergic neurons
Quality control: Comprehensive potency assays, sterility testing
Allogeneic: Off-the-shelf, HLA-matched cells

Aspen Neuroscience — ANPD001 (dRIP Trial)

[Aspen Neuroscience](/companies/aspen-neuroscience) is developing the first autologous (patient-specific) iPSC therapy for PD[@aspen].

Trial Details:

Design: First-in-human, patient-specific therapy
Approach: Patient's own skin or blood cells reprogrammed to iPSCs, then differentiated
Advantage: No immunosuppression required
Status: Phase 1/2 trial enrolling

Autologous Approach:

Patient-derived iPSCs eliminate immune rejection risk
Requires ~6-9 months for cell manufacturing per patient
CRISPR gene editing possible to correct genetic mutations
Higher cost and longer production time than allogeneic approaches

Kyoto University Program

The Kyoto University iPSC program, led by Dr. Jun Takahashi, represents the pioneering clinical effort in this field. Building on the work of Shinya Yamanaka (who won the Nobel Prize for discovering iPSC technology), this program has advanced autologous iPSC therapy for PD[@takahashi2023].

Key Features:

Autologous iPSCs derived from patient's own cells
First clinical trial initiated in Japan (2018)
Published safety data from initial patients
Demonstrated long-term cell survival in human brain

Cell Manufacturing Processes

iPSC Generation

Somatic Cell Collection: Patient's skin fibroblasts or blood cells are collected

Reprogramming: Cells are transfected with Yamanaka factors (OCT4, SOX2, KLF4, c-MYC)

iPSC Colony Selection: Individual colonies are picked and expanded

Characterization: Pluripotency confirmed via marker expression and teratoma formation

Dopaminergic Neuron Differentiation

The differentiation protocol follows stages that recapitulate human brain development:

Mermaid diagram (expand to render)

Key Protocols:

Floor Plate Induction: Using SHH and WNT signaling modulation
Midbrain Patterning: Specification to A9 subtype (substantia nigra neurons)
Neuronal Maturation: Maturation to post-mitotic dopaminergic neurons
Purification: Enrichment for TH-positive (tyrosine hydroxylase) neurons

Manufacturing Scale-Up

Challenges:

Scalable production while maintaining potency
Consistent differentiation efficiency
Cryopreservation and thawing viability
Quality control at each stage

Solutions:

Closed, automated bioreactor systems
Master cell bank approach
Defined media formulations
Standardized potency assays

Surgical Delivery

Stereotactic Neurosurgery

The standard delivery method for dopaminergic neuron transplantation is stereotactic neurosurgery[@stereotactic]:

Preoperative Planning:

High-resolution MRI for target identification
Trajectory planning to avoid blood vessels
Calculation of target coordinates

Surgical Procedure:

Patient under local or general anesthesia
Head fixed in stereotactic frame
Small burr hole made in skull
Cannula inserted to target coordinates

Cell Injection:

Cells delivered in suspension
Multiple injection tracks in putamen
Slow injection rate to prevent reflux
Bilateral implantation (both hemispheres)

Delivery Challenges

Targeting Precision: Submillimeter accuracy required
Cell Survival: Maximizing survival after transplantation
Immune Response: Managing host immune response to foreign cells
Distribution: Achieving uniform cell distribution in target region

Efficacy Data

Clinical Results to Date

Kyoto University (Autologous iPSC):

First patient treated in 2018
No serious adverse events reported
Preliminary evidence of motor symptom improvement
PET imaging showed surviving transplanted cells

BlueRock STEM-PD (Allogeneic hESC):

Primary endpoint: Safety and tolerability
Early data showed cells survived in all patients
Some patients showed improvement in OFF-medication UPDRS scores
No tumor formation detected

Preclinical Efficacy

In [non-human primate](/mechanisms/mptp-parkinson-model) models of PD:

Transplanted neurons survived for >2 years
Axonal outgrowth to striatum confirmed
Functional recovery in behavioral tests
No tumor formation in long-term studies

Comparison of Approaches

Autologous vs. Allogeneic

iPSC vs. ESC

Safety Considerations

Risks

Tumor Formation: Undifferentiated pluripotent cells could form teratomas

Immune Rejection: Host immune response to transplanted cells

Dyskinesias: Abnormal involuntary movements from over-dopamination

Infection: Surgical site infection or meningitis

Hemorrhage: Intracranial bleeding from surgery

Risk Mitigation

Comprehensive quality control to remove undifferentiated cells
HLA matching and immunosuppression for allogeneic cells
Careful dose titration
Sterile surgical techniques
Long-term monitoring

Investment Landscape

The iPSC cell therapy field for Parkinson's has attracted significant investment:

Companies in This Space

BlueRock Therapeutics (Bayer)

Lead program: BRT-DA01 (STEM-PD trial)
Allogeneic hESC-derived neurons
[Company page](/companies/bluerock-therapeutics)

Aspen Neuroscience

Lead program: ANPD001 (autologous)
Patient-specific iPSC approach
[Company page](/companies/aspen-neuroscience)

Cynata Therapeutics

Platform: Cymerus™ iPSC technology
iPSC-derived mesenchymal stem cells
[Company page](/companies/cynata-therapeutics)

Lundbeck/Oxford

Program: SC2587
ESC-derived dopaminergic neurons
Phase 1/2 trial in Europe

Future Directions

Next-Generation Approaches

Gene-Enhanced Cells: Engineering cells to express neurotrophic factors (GDNF, BDNF)

Encapsulated Cell Therapy: Using encapsulated cell devices for controlled factor delivery

Combination Approaches: Cell therapy combined with small molecules or immunomodulation

Induced Neurons (iN): Direct conversion of [astrocytes](/entities/astrocytes) to neurons

Challenges to Address

Improving cell survival and integration
Reducing manufacturing costs and time
Defining patient selection criteria
Establishing long-term efficacy
Achieving consistent clinical results

Cross-References

[Parkinson's Disease](/diseases/parkinsons-disease)
[Dopaminergic Neurons](/cell-types/vulnerable-dopaminergic-pd)
[Substantia Nigra in PD](/cell-types/substantia-nigra-dopamine-parkinsons)
[Nigrostriatal Pathway](/cell-types/nigrostriatal-terminals-parkinsons)
[Stem Cell Therapy Overview](/therapeutics/stem-cell-therapy)
[iPSC-Derived Dopaminergic Neurons](/cell-types/ipsc-derived-dopaminergic-neurons)
[BlueRock Therapeutics](/companies/bluerock-therapeutics)
[Aspen Neuroscience](/companies/aspen-neuroscience)
[Levodopa for PD](/therapeutics/levodopa)
[Deep Brain Stimulation](/therapeutics/deep-brain-stimulation-parkinson)
[GDNF Therapy](/therapeutics/gdnf-therapy-parkinsons)
[AADC Gene Therapy](/therapeutics/aadc-gene-therapy)
[Basal Ganglia Circuit](/circuits/parkinson-basal-ganglia-circuit)

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[Unknown, Dopaminergic Neuron Transplantation for Parkinson's Disease: Current Status and Future Prospects (n.d.)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

Unknown, STEM-PD Trial - BlueRock Therapeutics Phase 1 Study (n.d.)

Unknown, Aspen Neuroscience ANPD001 Autologous Cell Therapy (n.d.)

[Unknown, Takahashi J. (2023). iPS cell-based therapy for Parkinson's disease: A clinical trial update. Stem Cell Reports (2023)](https://doi.org/10.1016/j.stemcr.2022.12.001)

[Unknown, Stereotactic Transplantation of Stem Cell-Derived Dopamine Neurons for Parkinson's Disease (n.d.)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — 0.73 · Target: BDNF
[Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — 0.71 · Target: GLP1R, BDNF
[Vocal Cord Neuroplasticity Stimulation](/hypothesis/h-e0183502) — 0.48 · Target: CHR2/BDNF
[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — 0.44 · Target: TH, AADC
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — 0.77 · Target: SST
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — 0.76 · Target: ABCA1/LDLR/SREBF2

Related Analyses:

[Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) 🔄
[Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
[Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
[Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) 🔄

Pathway Diagram

The following diagram shows the key molecular relationships involving iPSC Cell Therapy for Parkinson's Disease discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

therapeutics-ipsc-cell-therapy-parkinsons

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-ipsc-cell-therapy-parkinsons
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-f55a5a00a446
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-ipsc-cell-therapy-parkinsons'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

169

Outgoing

240

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

iPSC Cell Therapy for Parkinson's Disease

iPSC Cell Therapy for Parkinson's Disease

Overview

iPSC Cell Therapy for Parkinson's Disease

Overview

Mechanism of Action

Cell Replacement Strategy

Target Brain Regions

Clinical Trial Landscape

Active Clinical Trials

UC San Diego — CT1-DAP001 (NCT06482268)

BlueRock Therapeutics — BRT-DA01 (STEM-PD)

Aspen Neuroscience — ANPD001 (dRIP Trial)

Kyoto University Program

Cell Manufacturing Processes

iPSC Generation

Dopaminergic Neuron Differentiation

Manufacturing Scale-Up

Surgical Delivery

Stereotactic Neurosurgery

Delivery Challenges

Efficacy Data

Clinical Results to Date

Preclinical Efficacy

Comparison of Approaches

Autologous vs. Allogeneic

iPSC vs. ESC

Safety Considerations

Risks

Risk Mitigation

Investment Landscape

Companies in This Space

BlueRock Therapeutics (Bayer)

Aspen Neuroscience

Cynata Therapeutics

Lundbeck/Oxford

Future Directions

Next-Generation Approaches

Challenges to Address

Cross-References

See Also

External Links

References

Related Hypotheses

Pathway Diagram

💬 Discussion